Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Synlogic Inc    SYBX

SYNLOGIC INC

(SYBX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Synlogic to Study SYNB1891 With Roche's Tecentriq in Advanced Solid Tumors

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/22/2019 | 08:06am EDT

By Colin Kellaher

Synlogic on Wednesday said it plans to study its SYNB1891 Synthetic Biotic medicine in combination with Roche Holding cancer immunotherapy Tecentriq in patients with advanced solid tumors under a collaboration with the Swiss drugmaker.

Synlogic, a Cambridge, Mass., clinical-stage biopharmaceutical company, said it expects to file an investigational new drug application with the U.S. Federal Drug Administration to begin an open-label Phase 1 clinical trial evaluating SYNB1891 as a monotherapy and a combination treatment with Tecentriq.

Synlogic said it will sponsor the study, while Roche will provide the clinical supply of Tecentriq.

Write to Colin Kellaher at colin.kellaher@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
ROCHE HOLDING -0.07% 275.2 Delayed Quote.15.12%
ROCHE HOLDING LTD. -0.26% 249.1 Delayed Quote.16.03%
ROCHE HOLDING LTD. -0.31% 275.65 Delayed Quote.13.50%
SYNLOGIC INC -1.40% 9.17 Delayed Quote.32.53%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SYNLOGIC INC
06/13SYNLOGIC : Ginkgo expand microbial discovery pact, throwing $80M investment into..
AQ
06/13SYNLOGIC : Ginkgo expand synthetic biology research pact
AQ
06/12SYNLOGIC, INC. : Entry into a Material Definitive Agreement, Unregistered Sale o..
AQ
06/12SYNLOGIC : and Ginkgo Bioworks Establish Transformational Platform Collaboration..
BU
06/05SYNLOGIC, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/22Synlogic to Study SYNB1891 With Roche's Tecentriq in Advanced Solid Tumors
DJ
05/22SYNLOGIC : Announces Clinical Collaboration to Evaluate SYNB1891 in Combination ..
BU
05/09SYNLOGIC : Reports First Quarter 2019 Financial Results and Provides Business Up..
BU
05/02SYNLOGIC : Announces First Quarter 2019 Conference Call and Webcast
BU
04/30SYNLOGIC : Presents Data Describing a Solid Oral Formulation Process for Synthet..
BU
More news
Financials ($)
Sales 2019 1,89 M
EBIT 2019 -61,3 M
Net income 2019 -59,1 M
Finance 2019 112 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 65,7x
EV / Sales 2020 104x
Capitalization 236 M
Chart SYNLOGIC INC
Duration : Period :
Synlogic Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SYNLOGIC INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 19,0 $
Spread / Average Target 105%
EPS Revisions
Managers
NameTitle
Aoife M. Brennan President, Chief Executive Officer & Director
Peter Barrett Chairman
Todd Shegog Chief Financial Officer
Paul S. Miller Chief Scientific Officer
Michael F. Powell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SYNLOGIC INC32.53%187
CSL LIMITED15.30%64 329
BIOGEN-21.60%43 310
ALEXION PHARMACEUTICALS30.42%25 574
SAMSUNG BIOLOGICS CO LTD--.--%16 821
GRIFOLS8.21%16 048